Review



monoclonal antibody against lp pla2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems monoclonal antibody against lp pla2
    Laboratory parameters in patients from different stenosis subtypes.
    Monoclonal Antibody Against Lp Pla2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibody against lp pla2/product/R&D Systems
    Average 93 stars, based on 21 article reviews
    monoclonal antibody against lp pla2 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis"

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    Journal: Frontiers in Neurology

    doi: 10.3389/fneur.2022.858302

    Laboratory parameters in patients from different stenosis subtypes.
    Figure Legend Snippet: Laboratory parameters in patients from different stenosis subtypes.

    Techniques Used:

    Serum lipoprotein-associated phospholipase A2 (Lp-PLA2) (A) and homocysteine (HCY) (B) levels in different stenosis subtypes. Lp-PLA2 levels were higher in the intracranial artery stenosis (ICAS) group than that in the other three groups, and the difference between the no cerebral artery stenosis (NCS) and ICAS groups was statistically significant (A) . The HCY level was significantly higher in the NCS group than in the intracranial and extracranial artery stenosis (IECS) group (B) .
    Figure Legend Snippet: Serum lipoprotein-associated phospholipase A2 (Lp-PLA2) (A) and homocysteine (HCY) (B) levels in different stenosis subtypes. Lp-PLA2 levels were higher in the intracranial artery stenosis (ICAS) group than that in the other three groups, and the difference between the no cerebral artery stenosis (NCS) and ICAS groups was statistically significant (A) . The HCY level was significantly higher in the NCS group than in the intracranial and extracranial artery stenosis (IECS) group (B) .

    Techniques Used:

    Percentage distribution of stenosis subtypes among the four quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2).
    Figure Legend Snippet: Percentage distribution of stenosis subtypes among the four quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2).

    Techniques Used:

    Distribution of different stenosis subtypes in the third (A) and fourth (B) quartiles of Lp-PLA2. The prevalence of NCS, ICAS, extracranial artery stenosis (ECAS), and IECS according to the level of Lp-PLA2. There was a trend toward an increased risk of ICAS in the third and fourth quartile.
    Figure Legend Snippet: Distribution of different stenosis subtypes in the third (A) and fourth (B) quartiles of Lp-PLA2. The prevalence of NCS, ICAS, extracranial artery stenosis (ECAS), and IECS according to the level of Lp-PLA2. There was a trend toward an increased risk of ICAS in the third and fourth quartile.

    Techniques Used:

    Serum Lp-PLA2 levels and the severity of stenosis in ICAS. (A) Serum levels of Lp-PLA2 levels according to the number of ICAS. Compared with those with one lesion and with no arterial stenosis, Lp-PLA2 levels in patients with two or more lesions were higher. (B) Serum levels of Lp-PLA2 levels according to the severity of stenosis of ICAS. Lp-PLA2 levels in patients with severe ICAS were relatively higher than in those with moderate or mild ICAS. (C) Serum levels of Lp-PLA2 levels according to symptomatic and asymptomatic ICAS. There was no difference in the Lp-PLA2 level between patients with asymptomatic and symptomatic ICAS.
    Figure Legend Snippet: Serum Lp-PLA2 levels and the severity of stenosis in ICAS. (A) Serum levels of Lp-PLA2 levels according to the number of ICAS. Compared with those with one lesion and with no arterial stenosis, Lp-PLA2 levels in patients with two or more lesions were higher. (B) Serum levels of Lp-PLA2 levels according to the severity of stenosis of ICAS. Lp-PLA2 levels in patients with severe ICAS were relatively higher than in those with moderate or mild ICAS. (C) Serum levels of Lp-PLA2 levels according to symptomatic and asymptomatic ICAS. There was no difference in the Lp-PLA2 level between patients with asymptomatic and symptomatic ICAS.

    Techniques Used:



    Similar Products

    monoclonal antibody against lp pla2  (R&D Systems)
    93
    R&D Systems monoclonal antibody against lp pla2
    Laboratory parameters in patients from different stenosis subtypes.
    Monoclonal Antibody Against Lp Pla2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibody against lp pla2/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    monoclonal antibody against lp pla2 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    monoclonal antibody against lp pla 2  (R&D Systems)
    86
    R&D Systems monoclonal antibody against lp pla 2
    Clinical characteristics of hypertensive patients according to location and severity of arterial stenosis.
    Monoclonal Antibody Against Lp Pla 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibody against lp pla 2/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    monoclonal antibody against lp pla 2 - by Bioz Stars, 2026-02
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Laboratory parameters in patients from different stenosis subtypes.

    Journal: Frontiers in Neurology

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    doi: 10.3389/fneur.2022.858302

    Figure Lengend Snippet: Laboratory parameters in patients from different stenosis subtypes.

    Article Snippet: In brief, the serum was added to a microtiter plate that was pre-immobilized with a monoclonal antibody against Lp-PLA2 or hs-CRP (DPLG70, QK1707, R&D System, USA) and then incubated with anti-Lp-PLA2 or anti-hs-CRP antibody labeled with horseradish peroxidase.

    Techniques:

    Serum lipoprotein-associated phospholipase A2 (Lp-PLA2) (A) and homocysteine (HCY) (B) levels in different stenosis subtypes. Lp-PLA2 levels were higher in the intracranial artery stenosis (ICAS) group than that in the other three groups, and the difference between the no cerebral artery stenosis (NCS) and ICAS groups was statistically significant (A) . The HCY level was significantly higher in the NCS group than in the intracranial and extracranial artery stenosis (IECS) group (B) .

    Journal: Frontiers in Neurology

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    doi: 10.3389/fneur.2022.858302

    Figure Lengend Snippet: Serum lipoprotein-associated phospholipase A2 (Lp-PLA2) (A) and homocysteine (HCY) (B) levels in different stenosis subtypes. Lp-PLA2 levels were higher in the intracranial artery stenosis (ICAS) group than that in the other three groups, and the difference between the no cerebral artery stenosis (NCS) and ICAS groups was statistically significant (A) . The HCY level was significantly higher in the NCS group than in the intracranial and extracranial artery stenosis (IECS) group (B) .

    Article Snippet: In brief, the serum was added to a microtiter plate that was pre-immobilized with a monoclonal antibody against Lp-PLA2 or hs-CRP (DPLG70, QK1707, R&D System, USA) and then incubated with anti-Lp-PLA2 or anti-hs-CRP antibody labeled with horseradish peroxidase.

    Techniques:

    Percentage distribution of stenosis subtypes among the four quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2).

    Journal: Frontiers in Neurology

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    doi: 10.3389/fneur.2022.858302

    Figure Lengend Snippet: Percentage distribution of stenosis subtypes among the four quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2).

    Article Snippet: In brief, the serum was added to a microtiter plate that was pre-immobilized with a monoclonal antibody against Lp-PLA2 or hs-CRP (DPLG70, QK1707, R&D System, USA) and then incubated with anti-Lp-PLA2 or anti-hs-CRP antibody labeled with horseradish peroxidase.

    Techniques:

    Distribution of different stenosis subtypes in the third (A) and fourth (B) quartiles of Lp-PLA2. The prevalence of NCS, ICAS, extracranial artery stenosis (ECAS), and IECS according to the level of Lp-PLA2. There was a trend toward an increased risk of ICAS in the third and fourth quartile.

    Journal: Frontiers in Neurology

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    doi: 10.3389/fneur.2022.858302

    Figure Lengend Snippet: Distribution of different stenosis subtypes in the third (A) and fourth (B) quartiles of Lp-PLA2. The prevalence of NCS, ICAS, extracranial artery stenosis (ECAS), and IECS according to the level of Lp-PLA2. There was a trend toward an increased risk of ICAS in the third and fourth quartile.

    Article Snippet: In brief, the serum was added to a microtiter plate that was pre-immobilized with a monoclonal antibody against Lp-PLA2 or hs-CRP (DPLG70, QK1707, R&D System, USA) and then incubated with anti-Lp-PLA2 or anti-hs-CRP antibody labeled with horseradish peroxidase.

    Techniques:

    Serum Lp-PLA2 levels and the severity of stenosis in ICAS. (A) Serum levels of Lp-PLA2 levels according to the number of ICAS. Compared with those with one lesion and with no arterial stenosis, Lp-PLA2 levels in patients with two or more lesions were higher. (B) Serum levels of Lp-PLA2 levels according to the severity of stenosis of ICAS. Lp-PLA2 levels in patients with severe ICAS were relatively higher than in those with moderate or mild ICAS. (C) Serum levels of Lp-PLA2 levels according to symptomatic and asymptomatic ICAS. There was no difference in the Lp-PLA2 level between patients with asymptomatic and symptomatic ICAS.

    Journal: Frontiers in Neurology

    Article Title: Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

    doi: 10.3389/fneur.2022.858302

    Figure Lengend Snippet: Serum Lp-PLA2 levels and the severity of stenosis in ICAS. (A) Serum levels of Lp-PLA2 levels according to the number of ICAS. Compared with those with one lesion and with no arterial stenosis, Lp-PLA2 levels in patients with two or more lesions were higher. (B) Serum levels of Lp-PLA2 levels according to the severity of stenosis of ICAS. Lp-PLA2 levels in patients with severe ICAS were relatively higher than in those with moderate or mild ICAS. (C) Serum levels of Lp-PLA2 levels according to symptomatic and asymptomatic ICAS. There was no difference in the Lp-PLA2 level between patients with asymptomatic and symptomatic ICAS.

    Article Snippet: In brief, the serum was added to a microtiter plate that was pre-immobilized with a monoclonal antibody against Lp-PLA2 or hs-CRP (DPLG70, QK1707, R&D System, USA) and then incubated with anti-Lp-PLA2 or anti-hs-CRP antibody labeled with horseradish peroxidase.

    Techniques:

    Journal: PLoS ONE

    Article Title: Association of Lp-PLA 2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients

    doi: 10.1371/journal.pone.0130473

    Figure Lengend Snippet: Clinical characteristics of hypertensive patients according to location and severity of arterial stenosis.

    Article Snippet: Samples were incubated in microtitre plate wells with immobilized monoclonal antibody against Lp-PLA 2 (R&D AF5106,MN，USA), and then it was identified by an anti-Lp-PLA 2 antibody labeled with horseradish peroxidase.

    Techniques: